A peer-reviewed study of Exact Sciences‘ Cologuard confirmed its ability to detect colorectal cancer, the organization announced today.

According to a release, Cologuard detected 100 percent of colorectal cancers and 52 percent of significant premalignant lesions in 661 average-risk Alaska Native people between the ages of 40-85.

“This study of Alaska Native people confirms the power of Cologuard and reaffirms its importance in our effort to increase America’s stagnating colon cancer screening rates,” Exact Sciences CEO Kevin Conroy said in a statement. “Not only did Cologuard’s sensitivity remain high across all cancer stages and pre-cancers, but its false positive rate decreased. Cologuard’s performance highlights its role as a screening option.”

The study is published in the Mayo Clinic Proceedings.